Drug intelligence / Profile preview

BCI-XXX

Development stage: Preclinical
Lead developer: Mithra Pharmaceuticals
Modality: Small Molecules

Overview

BCI-XXX is a preclinical-stage small molecule inhibitor of the colony-stimulating factor 1 receptor (CSF1R), developed by BCI Pharma. CSF1R is a key regulator of the survival, proliferation, and differentiation of mononuclear phagocytes, including microglia in the central nervous system. By inhibiting CSF1R, BCI-XXX aims to modulate microglial activity and reduce central neuroinflammation, which is a contributing factor in various neurodegenerative and neurological disorders. The program was highlighted in BCI Pharma's 2019 pipeline specifically for central neuroinflammation.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on BCI-XXX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCI-XXX.

Explore the full profile